A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News

Indivior Pharmaceuticals (INDV) is back on investors’ radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase plan.

See our latest analysis for Indivior Pharmaceuticals.

The recent Q1 beat, raised 2026 guidance, and the new accelerated share repurchase agreement have all coincided with strong momentum, with a 27.93% 1 month share price return and a very large 1 year total shareholder return that far outpaces typical market levels.

If Indivior’s run has you looking for the next opportunity in healthcare and biotech, it could be a good time to scan 33 healthcare AI stocks.

With earnings, guidance, and buybacks all moving in the same direction, Indivior now trades at what some models suggest is a sizeable intrinsic discount. This raises the question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 3% Overvalued

The most followed valuation narrative puts Indivior’s fair value at $37.86, slightly below the last close of $38.98, which suggests a modest premium today.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Read the complete narrative.

Want to see what kind of revenue trajectory and margin profile has to materialize to back that fair value, including how much earnings power the narrative is baking in and what sort of valuation multiple it assumes on those future profits?

Result: Fair Value of $37.86 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, if SUBLOCADE adoption, the Move Forward in Recovery campaign, and the Indivior Action Agenda outperform current assumptions, earnings and valuation could outpace this slightly overvalued narrative.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Another Angle on Value

The analyst narrative suggests Indivior is about 3% overvalued around $37.86, yet our DCF model points the other way. On that view, the stock at $38.98 sits roughly 64% below an estimated future cash flow value of $108.90. Which story do you rely on more: the earnings multiple or the cash flow math?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment clearly mixed between upside potential and real concerns, this is the moment to review the data yourself and move quickly to form a view using 4 key rewards and 3 important warning signs

Looking for more investment ideas?

Do not stop with a single stock story. Widen your opportunity set now using focused stock lists that highlight different strengths investors often look for.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com